Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026

A clinical update reported meaningful disease-activity improvement in 8 of 9 evaluable patients, including rapid, marked reductions in proteinuria and complete renal responses. The brief report provides no trial phase, comparator, or further outcome details.